The Virus and It’s Effect

“Rotavirus is a contagious virus that can cause gastroenteritis (inflammation of the stomach and intestines). Symptoms include severe watery diarrhea, often with vomiting, fever, and abdominal pain.” – CDC, 2014

Annual U.S. Mortality Rate for Rotavirus

Between 20-60 deaths per year – CDC, 2014

---

The Dangers of the Vaccines

The Current Rotavirus Vaccines, Rotarix & RotaTeq

Below are the two vaccines that currently administered in the U.S:

RotaTeq® (RV5) is given in 3 doses at ages 2 months, 4 months, and 6 months.
Rotarix® (RV1) is given in 2 doses at ages 2 months and 4 months.

Rotarix (RV1)

“From 2008 through April 2012, VAERS received 58 reports of confirmed intussusception following Rotarix.” – CDC, 2014

“Intussusception is a process in which a segment of intestine invaginates into the adjoining intestinal lumen, causing bowel obstruction. With early diagnosis, appropriate fluid resuscitation, and therapy, the mortality rate from intussusception in children is less than 1%. If left untreated, however, this condition is uniformly fatal in 2-5 days.” – Medscape, 2014

RotaTeq (RV5)

Increased the Side Effects vs Placebo – FDA, 2014

• Diarrhea (24.1% vaccine vs 21.3% placebo)
• Vomiting (15.2% vaccine vs 13.6% placebo)
• Ear infection (14.5% vaccine vs 13.0% placebo)
• Runny nose and sore throat (6.9% vaccine vs 5.8% placebo)
• Wheezing and coughing (1.1% vaccine vs 0.7% placebo)

Also, RV5 vaccine has been shown to have a shedding effect of the virus within just a couple days of the infants vaccination. Viral shedding refers to the “process that occurs when a virus is present in bodily fluids or open wounds and can thereby be transmitted to another person, as with herpetic lesions,” according to The Free Dictionary, 2015.

“Vaccine-type rotavirus was detected in all 50 antigen-positive specimens and 8 of 8 antigen-negative specimens. Nine (75%) of 12 EIA-positive and 1 EIA-negative samples tested culture-positive for vaccine-type rotavirus. Fecal shedding of rotavirus vaccine virus after the first dose of RV5 occurred over a wide range of post-vaccination days not previously studied.” – Vaccine, 2011

“We document here the occurrence of vaccine-derived rotavirus (RotaTeq [Merck and Co, Whitehouse Station, NJ]) transmission from a vaccinated infant to an older, unvaccinated sibling, resulting in symptomatic rotavirus gastroenteritis that required emergency department care.” – Journal of Pediatrics, 2009

“The analyses included 507,874 first doses and 1,277,556 total doses of RV5…The number of excess cases of intussusception per 100,000 recipients of the first dose of RV5 was significantly elevated, both in the primary analysis (attributable risk, 1.1 [95% confidence interval, 0.3 to 2.7] for the 7-day risk window and 1.5 [95% CI, 0.2 to 3.2] for the 21-day risk window) and in the secondary analysis (attributable risk, 1.2 [95% CI, 0.2 to 3.2] for the 21-day risk window).” – The New England Journal of Medicine, 2014

The Former Rotavirus Vaccine

RotaShield (RRV-TV)

“On July 16, 1999, CDC recommended that health-care providers suspend use of the licensed rhesus-human rotavirus reassortant-tetravalent vaccine (RRV-TV) (RotaShield®, Wyeth Laboratories, Inc.” due to increased risk of Intussusception).” – CDC, 2004

“Assuming full implementation of a national program of vaccination with RRV-TV, we estimated that 1 case of intussusception attributable to the vaccine would occur for every 4670 to 9474 infants vaccinated.” – New England Journal of Medicine, 2001